Cross Infection: Clinical Trials

4 trials for Cross Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 unknown. 4 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Unknown 4
Phase 23Unknown 3

Follow Cross Infection: new trials by email Literature Review of Cross Infection trials Research Report on Cross Infection

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia
TP-122A - Pneumonia, Ventilator-Associated
Phase 1 / Phase 2UnknownTechnophage, SA152024-09-012024-04-17
Safety of Nebulized Combination Therapy BromAcĀ® in COVID-19 Respiratory Disease
Bromelains, Acetylcysteine - COVID-19 Pneumonia, COVID-19
Phase 1 / Phase 2UnknownMucpharm Pty Ltd302022-05-012022-02-28
Impact of Daily Bathing With Chlorhexidine in the Critical Patient
Daily baths with chlorhexidine wipes, oral spray and standard shampoo, Daily baths with placebo wipes, oral spray and shampoo - Healthcare Associated Infections
Phase 1UnknownUniversidad Autonoma de Nuevo Leon402016-08-012016-08-17
Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants
Talactoferrin, Placebo - Nosocomial Infections
Phase 1 / Phase 2UnknownAgennix1202009-06-012012-03-15

Narrower conditions

Pneumonia, Ventilator-Associated (2)  ·  COVID-19 (1)

Broader conditions

Disease Attributes (4)  ·  Iatrogenic Disease (4)  ·  Infections (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Healthcare-Associated Pneumonia (2)  ·  Lung Diseases (2)  ·  Pneumonia (2)  ·  Respiratory Tract Diseases (2)  ·  Respiratory Tract Infections (2)  ·  Coronaviridae Infections (1)  ·  Coronavirus Infections (1)  ·  Nidovirales Infections (1)  ·  Pneumonia, Viral (1)

Interventions

Acetylcysteine (1)  ·  Bromelains (1)  ·  Oral Sprays (1)  ·  talactoferrin alfa (1)

Sponsors

Agennix (1)  ·  Mucpharm Pty Ltd (1)  ·  Technophage, SA (1)  ·  Universidad Autonoma de Nuevo Leon (1)

Countries

France (1)  ·  United States (1)

Top investigators

Frank MP van Haren, MD, PhD (1)  ·  Margarida Barreto, Msc (1)  ·  Michel F Martinez-Resendez, M.D. (1)

Results publications

PMID 27234409, PMID 27260839

NIH funding

R44HD057744 (1)